Status:
COMPLETED
Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors
Lead Sponsor:
Northwestern University
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Skin Rash
Eligibility:
All Genders
Brief Summary
The purpose of this study is to characterize the microscopic findings of skin rash associated with the use of chemotherapeutic anticancer agents known as epidermal growth factor inhibitors (EGFRIs).
Detailed Description
Epidermal growth factor (EGF) and its receptor, the EGFR, are known to be key drivers in cellular proliferation and survival. Malignant tumors result from uncontrolled cell proliferation. The use of d...
Eligibility Criteria
Inclusion
- Patients treated with lapatinib who developed skin toxicities and were biopsied.
- Patients treated with erlotinib, cetuximab, or panitumumab who have been biopsied for skin rash.
Exclusion
- Patients who do not fit above criteria.
Key Trial Info
Start Date :
April 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00709878
Start Date
April 1 2008
End Date
August 1 2010
Last Update
March 17 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern University
Chicago, Illinois, United States, 60611